nucleophosmin 1
Last updated 18 Aug 2020
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
The NPM1 gene provides instructions for making a protein called nucleophosmin, which is found in a small region inside the nucleus of the cell called the nucleolus. Nucleophosmin shuttles back and forth between the nucleus and the fluid surrounding it (the cytoplasm). It is thought to play a part in many cellular functions, including processes involved in protein formation, DNA replication, and the progression of the cell through the step-by-step process it takes to replicate itself (called the cell cycle). In the nucleolus, nucleophosmin attaches to another protein called ARF, keeping it in the proper location and protecting it from being broken down. The ARF protein is considered a tumour suppressor because it is involved in pathways that prevent cells from growing and dividing in an uncontrolled way.
Video picks for GenesVideo library
Normal function
The NPM1 gene provides instructions for making a protein called nucleophosmin, which is found in a small region inside the nucleus of the cell called the nucleolus. Nucleophosmin shuttles back and forth between the nucleus and the fluid surrounding it (the cytoplasm). It is thought to play a part in many cellular functions, including processes involved in protein formation, DNA replication, and the progression of the cell through the step-by-step process it takes to replicate itself (called the cell cycle). In the nucleolus, nucleophosmin attaches to another protein called ARF, keeping it in the proper location and protecting it from being broken down. The ARF protein is considered a tumour suppressor because it is involved in pathways that prevent cells from growing and dividing in an uncontrolled way.
Conditions referring to this gene or chromosome
Other names
B23
NPM
NPM_HUMAN
nucleolar protein NO38
nucleophosmin
nucleophosmin (nucleolar phosphoprotein B23, numatrin)
nucleophosmin/nucleoplasmin family, member 1
Patient picks for Genes

PID Q&A
Does PID cause bleeding?
Dr Sarah Jarvis MBE Symptoms may develop quickly. You can become quite ill over a few days. Sometimes symptoms are mild and develop slowly. For example, you may just have a mild abdominal pain that may 'grumble on' for weeks. In some cases no symptoms develop and you do not know that you are infected. However, you are still at risk of complications even if you have no symptoms at first. [https://patient.info/health/pelvic-pain-in-women/pelvic-inflammatory-disease#nav-1](https://patient.info/health/pelvic-pain-in-women/pelvic-inflammatory-disease#nav-1)
by Dr Sarah Jarvis

Risks of diabetes
What can someone with type 1 diabetes do to stop their glucose going too high?
Dr Sarah Jarvis MBE For more information on continuous glucose monitoring, go to [https://patient.info/health/type-1-diabetes/features/continuous-glucose-monitoring-in-type-1-diabetes](https://patient.info/health/type-1-diabetes/features/continuous-glucose-monitoring-in-type-1-diabetes)
by Dr Sarah Jarvis

Diabetes Q&A
Can you drive if you have diabetes?
Dr Sarah Jarvis MBE Hypos can cause drowsiness, dizziness and confusion: in severe cases they can lead to loss of consciousness or even be fatal. But hypos can also affect your ability to drive safely. So the DVLA has set out guidelines for people with all diabetes - and whether you have type 1 or type 2 diabetes, you need to know about them. For more information on diabetes and driving, go to [https://patient.info/health/diabetes-mellitus-leaflet/driving-and-diabetes](https://patient.info/health/diabetes-mellitus-leaflet/driving-and-diabetes)
by Dr Sarah Jarvis

Risks of diabetes
How can I avoid getting a hypo?
Dr Sarah Jarvis MBE Hypoglycaemia, or low blood sugar, is often known as a 'hypo'. It can make you feel unwell and affect your ability to drive. Simple steps will reduce the risk, and allow you to treat a hypo early, before it causes more serious complications. For more information, go to [https://patient.info/health/type-1-diabetes/features/how-low-blood-sugar-is-dangerous](https://patient.info/health/type-1-diabetes/features/how-low-blood-sugar-is-dangerous)
by Dr Sarah Jarvis

Other diabetes
What does insulin do?
Dr Partha Kar In type 1 diabetes, the body stops making insulin and the blood sugar level goes very high. Some people who have type 2 diabetes may also need to have insulin injections to help control blood sugar levels. Insulin is usually injected under the skin between 2-4 times a day. For more information on insulin, go to [https://patient.info/health/type-1-diabetes/insulins](https://patient.info/health/type-1-diabetes/insulins)
by Dr Partha Kar, FRCP

Meningitis Q&A
Why do teenagers need a meningitis vaccine?
Dr Sarah Jarvis MBE If you are under the age of 25 and have not been immunised, see your doctor or practice nurse to get immunised. This is particularly important if you are about to start university for the first time, as the risk of infection with group W meningococcus is highest in first-year university students. Just one injection of vaccine is needed if you are over the age of 1 year. For more information on the meningitis vaccine, go to [https://patient.info/health/meningitis-leaflet/meningococcal-meningitis-vaccine](https://patient.info/health/meningitis-leaflet/meningococcal-meningitis-vaccine)
by Dr Sarah Jarvis
Related patient information and medicines

Patient information leaflet
Giant Cell Arteritis
Giant cell arteritis (temporal arteritis) causes No one really knows exactly what causes giant cell arteritis (temporal arteritis). We do know that there are genetic changes in some people which make them more likely to develop giant cell (temporal) arteritis. Because the dose of steroids for giant cell (temporal) arteritis is high, everyone who.

Patient information leaflet
Wilson's disease
Wilson's disease is a genetic disorder in which copper builds up in the body, mainly in the liver and brain. Without any treatment, the build-up of copper can cause serious symptoms. Treatment is with medication to remove the excess copper and/or to prevent a further build-up of copper. What is Wilson's disease. Wilson's disease is a condition.

Patient information leaflet
Immunisation for flu
Influenza (flu) Flu is a common viral infection that tends to be most common in the winter. Flu can cause much more severe symptoms than the common cold Common cold. Some people can become seriously ill with flu, needing hospital treatment, and it can be life-threatening. Certain groups of people, such as older adults and young children, are at.

Patient information leaflet
Atrial fibrillation and stroke prevention
The medicines used to prevent a atrial fibrillation-related stroke are called anticoagulants. These help to stop blood clots forming in your blood vessels. Why does atrial fibrillation increase your risk of having a stroke. The main complication of atrial fibrillation (AF) Atrial fibrillation is an increased risk of having a stroke Stroke. AF can.

Patient information leaflet
Type 2 diabetes treatment
As soon as. If you are already taking metformin, your doctor should add in an SGLT-2 inhibitor. If you are taking metformin and other treatment(s), your doctor may discuss with you replacing one of your other treatments with an SGLT-2 inhibitor. Your doctor should offer or consider adding an SGLT-2 inhibitor regardless of your blood glucose.

Patient information leaflet
Diabetic kidney disease
This scarring process in the glomeruli is called glomerulosclerosis. It usually takes several years for glomerulosclerosis to develop and it only happens in some people with diabetes. As the condition becomes worse, scarred tissue (glomerulosclerosis) gradually replaces healthy kidney tissue. As a result, the kidneys become less and less able to.
Further reading and references
- nucleophosmin 1; MedlinePlus, National Library of Medicine.
- Andraos E, Dignac J, Meggetto F. NPM-ALK: A Driver of Lymphoma Pathogenesis and a Therapeutic Target. Cancers (Basel). 2021 Jan 5;13(1):144. doi: 10.3390/cancers13010144.
- Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, Wang SA, Bagg A, Barbui T, Branford S, Bueso-Ramos CE, Cortes JE, Dal Cin P, DiNardo CD, Dombret H, Duncavage EJ, Ebert BL, Estey EH, Facchetti F, Foucar K, Gangat N, Gianelli U, Godley LA, Gokbuget N, Gotlib J, Hellstrom-Lindberg E, Hobbs GS, Hoffman R, Jabbour EJ, Kiladjian JJ, Larson RA, Le Beau MM, Loh ML, Lowenberg B, Macintyre E, Malcovati L, Mullighan CG, Niemeyer C, Odenike OM, Ogawa S, Orfao A, Papaemmanuil E, Passamonti F, Porkka K, Pui CH, Radich JP, Reiter A, Rozman M, Rudelius M, Savona MR, Schiffer CA, Schmitt-Graeff A, Shimamura A, Sierra J, Stock WA, Stone RM, Tallman MS, Thiele J, Tien HF, Tzankov A, Vannucchi AM, Vyas P, Wei AH, Weinberg OK, Wierzbowska A, Cazzola M, Dohner H, Tefferi A. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 Sep 15;140(11):1200-1228. doi: 10.1182/blood.2022015850.
- Arellano ML, Thirman MJ, DiPersio JF, Heiblig M, Stein EM, Schuh AC, Zucenka A, de Botton S, Grove CS, Mannis GN, Papayannidis C, Perl AE, Issa GC, Aldoss I, Bajel A, Dickens DS, Kuhn MWM, Mantzaris I, Raffoux E, Traer E, Amitai I, Dohner H, Greco C, Kovacsovics T, McMahon CM, Montesinos P, Pigneux A, Shami PJ, Stone RM, Wolach O, Harpel JG, Chudnovsky Y, Yu L, Bagley RG, Smith AR, Blachly JS. Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study. Blood. 2025 Aug 28;146(9):1065-1077. doi: 10.1182/blood.2025028357.
- Colombo E, Martinelli P, Zamponi R, Shing DC, Bonetti P, Luzi L, Volorio S, Bernard L, Pruneri G, Alcalay M, Pelicci PG. Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant. Cancer Res. 2006 Mar 15;66(6):3044-50. doi: 10.1158/0008-5472.CAN-05-2378.
- Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Lowenberg B, Bloomfield CD; European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010 Jan 21;115(3):453-74. doi: 10.1182/blood-2009-07-235358. Epub 2009 Oct 30.
- Falini B, Bolli N, Shan J, Martelli MP, Liso A, Pucciarini A, Bigerna B, Pasqualucci L, Mannucci R, Rosati R, Gorello P, Diverio D, Roti G, Tiacci E, Cazzaniga G, Biondi A, Schnittger S, Haferlach T, Hiddemann W, Martelli MF, Gu W, Mecucci C, Nicoletti I. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood. 2006 Jun 1;107(11):4514-23. doi: 10.1182/blood-2005-11-4745. Epub 2006 Feb 2.
- Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, La Starza R, Diverio D, Colombo E, Santucci A, Bigerna B, Pacini R, Pucciarini A, Liso A, Vignetti M, Fazi P, Meani N, Pettirossi V, Saglio G, Mandelli F, Lo-Coco F, Pelicci PG, Martelli MF; GIMEMA Acute Leukemia Working Party. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005 Jan 20;352(3):254-66. doi: 10.1056/NEJMoa041974.
- Falini B, Nicoletti I, Bolli N, Martelli MP, Liso A, Gorello P, Mandelli F, Mecucci C, Martelli MF. Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. Haematologica. 2007 Apr;92(4):519-32. doi: 10.3324/haematol.11007.
- Falini B, Sorcini D, Perriello VM, Sportoletti P. Functions of the native NPM1 protein and its leukemic mutant. Leukemia. 2025 Feb;39(2):276-290. doi: 10.1038/s41375-024-02476-4. Epub 2024 Dec 17.
- Gu X, Ebrahem Q, Mahfouz RZ, Hasipek M, Enane F, Radivoyevitch T, Rapin N, Przychodzen B, Hu Z, Balusu R, Cotta CV, Wald D, Argueta C, Landesman Y, Martelli MP, Falini B, Carraway H, Porse BT, Maciejewski J, Jha BK, Saunthararajah Y. Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates. J Clin Invest. 2018 Oct 1;128(10):4260-4279. doi: 10.1172/JCI97117. Epub 2018 Jul 17.
- Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, Thirman MJ, Patel MR, Dickens DS, Shenoy S, Shukla N, Kantarjian H, Armstrong SA, Perner F, Perry JA, Rosen G, Bagley RG, Meyers ML, Ordentlich P, Gu Y, Kumar V, Smith S, McGeehan GM, Stein EM. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023 Mar;615(7954):920-924. doi: 10.1038/s41586-023-05812-3. Epub 2023 Mar 15.
- Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022 Jul;36(7):1703-1719. doi: 10.1038/s41375-022-01613-1. Epub 2022 Jun 22.
- Li J, Sejas DP, Rani R, Koretsky T, Bagby GC, Pang Q. Nucleophosmin regulates cell cycle progression and stress response in hematopoietic stem/progenitor cells. J Biol Chem. 2006 Jun 16;281(24):16536-45. doi: 10.1074/jbc.M601386200. Epub 2006 Apr 11.
- Mat Yusoff Y, Abu Seman Z, Othman N, Kamaluddin NR, Esa E, Zulkiply NA, Abdullah J, Zakaria Z. Identification of FLT3 and NPM1 Mutations in Patients with Acute Myeloid Leukaemia. Asian Pac J Cancer Prev. 2019 Jun 1;20(6):1749-1755. doi: 10.31557/APJCP.2019.20.6.1749.
- Ningombam A, Verma D, Kumar R, Singh J, Ali MS, Pandey AK, Singh I, Bakhshi S, Sharma A, Pushpam D, Palanichamy JK, Tanwar P, Singh AR, Chopra A. Prognostic relevance of NPM1, CEBPA, and FLT3 mutations in cytogenetically normal adult AML patients. Am J Blood Res. 2023 Feb 15;13(1):28-43. eCollection 2023.
- Niparuck P, Limsuwanachot N, Pukiat S, Chantrathammachart P, Rerkamnuaychoke B, Magmuang S, Phusanti S, Boonyawat K, Puavilai T, Angchaisuksiri P, Ungkanont A, Chuncharunee S. Cytogenetics and FLT3-ITD mutation predict clinical outcomes in non transplant patients with acute myeloid leukemia. Exp Hematol Oncol. 2019 Jan 30;8:3. doi: 10.1186/s40164-019-0127-z. eCollection 2019.
- Othman J, Potter N, Ivey A, Jovanovic J, Runglall M, Freeman SD, Gilkes A, Thomas I, Johnson S, Canham J, Cavenagh J, Kottaridis P, Arnold C, Ommen HB, Overgaard UM, Dennis M, Burnett A, Wilhelm-Benartzi C, Dillon R, Russell NH. Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission. Blood. 2024 May 9;143(19):1931-1936. doi: 10.1182/blood.2023023096.
- Othman J, Potter N, Ivey A, Tazi Y, Papaemmanuil E, Jovanovic J, Freeman SD, Gilkes A, Gale R, Rapoz-D'Silva T, Runglall M, Kleeman M, Dhami P, Thomas I, Johnson S, Canham J, Cavenagh J, Kottaridis P, Arnold C, Ommen HB, Overgaard UM, Dennis M, Burnett A, Wilhelm-Benartzi C, Huntly B, Russell NH, Dillon R. Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML. Blood. 2024 Aug 15;144(7):714-728. doi: 10.1182/blood.2024024310.
- Pastore F, Pastore A, Rothenberg-Thurley M, Metzeler KH, Ksienzyk B, Schneider S, Bohlander SK, Braess J, Sauerland MC, Gorlich D, Berdel WE, Wormann B, von Bergwelt-Baildon MS, Hiddemann W, Spiekermann K. Molecular profiling of patients with cytogenetically normal acute myeloid leukemia and hyperleukocytosis. Cancer. 2022 Dec 15;128(24):4213-4222. doi: 10.1002/cncr.34495. Epub 2022 Oct 22.
- Sharma N, Liesveld JL. NPM 1 Mutations in AML-The Landscape in 2023. Cancers (Basel). 2023 Feb 12;15(4):1177. doi: 10.3390/cancers15041177.
- Sherr CJ. Divorcing ARF and p53: an unsettled case. Nat Rev Cancer. 2006 Sep;6(9):663-73. doi: 10.1038/nrc1954. Epub 2006 Aug 17.
Share your thoughts or experiences with others in our patient communities.
Sign up to the Patient newsletter
Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.

